{"id":"https://openalex.org/W2007416161","doi":"https://doi.org/10.4088/jcp.v63n0203","title":"Obsessive-Compulsive Symptoms During Treatment With Olanzapine and Risperidone: A Prospective Study of 113 Patients With Recent-Onset Schizophrenia or Related Disorders","display_name":"Obsessive-Compulsive Symptoms During Treatment With Olanzapine and Risperidone: A Prospective Study of 113 Patients With Recent-Onset Schizophrenia or Related Disorders","alternate_titles":[],"publication_year":2002,"publication_date":"2002-02-15","ids":{"openalex":"https://openalex.org/W2007416161","doi":"https://doi.org/10.4088/jcp.v63n0203","mag":"2007416161","pmid":"https://pubmed.ncbi.nlm.nih.gov/11874209"},"language":"en","primary_location":{"id":"doi:10.4088/jcp.v63n0203","doi":"https://doi.org/10.4088/jcp.v63n0203","is_oa":false,"landing_page_url":"https://doi.org/10.4088/jcp.v63n0203","pdf_url":null,"source":{"id":"https://openalex.org/S17992710","display_name":"The Journal of Clinical Psychiatry","issn_l":"0160-6689","issn":["0160-6689","1534-8628","1555-2101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4322614534","host_organization_name":"Physicians Postgraduate Press, Inc.","host_organization_lineage":["https://openalex.org/P4322614534"],"host_organization_lineage_names":["Physicians Postgraduate Press, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Psychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2007416161"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049205174","display_name":"Lieuwe de Haan","orcid":"https://orcid.org/0000-0002-3820-7926","observed_orcids":["https://orcid.org/0000-0002-3820-7926"]},"institutions":[{"id":"https://openalex.org/I2802928900","display_name":"Amsterdam UMC Location University of Amsterdam","ror":"https://ror.org/03t4gr691","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2802928900","https://openalex.org/I4210151833"]},{"id":"https://openalex.org/I887064364","display_name":"University of Amsterdam","ror":"https://ror.org/04dkp9463","country_code":"NL","type":"education","lineage":["https://openalex.org/I887064364"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lieuwe de Haan","raw_affiliation_strings":["Adolescent Clinic, Academic Medical Center, University ofAmsterdam, Department of Psychiatry, The Netherlands. l.dehaan@amc.uva.nl","Adolescent Clinic, Academic Medical Center, University ofAmsterdam, Department of Psychiatry, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Adolescent Clinic, Academic Medical Center, University ofAmsterdam, Department of Psychiatry, The Netherlands. l.dehaan@amc.uva.nl","institution_ids":["https://openalex.org/I2802928900","https://openalex.org/I887064364"]},{"raw_affiliation_string":"Adolescent Clinic, Academic Medical Center, University ofAmsterdam, Department of Psychiatry, The Netherlands","institution_ids":["https://openalex.org/I2802928900","https://openalex.org/I887064364"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005329520","display_name":"Nico Beuk","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nico Beuk","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003409212","display_name":"Britt Hoogenboom","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Britt Hoogenboom","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111683026","display_name":"Peter M. A. J. Dingemans","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter Dingemans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5041329015","display_name":"DON H. LINSZEN","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Don Linszen","raw_affiliation_strings":["Adult Psychiatry"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Adult Psychiatry","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.83,"has_fulltext":false,"cited_by_count":119,"citation_normalized_percentile":{"value":0.93109382,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"63","issue":"2","first_page":"104","last_page":"107"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11123","display_name":"Obsessive-Compulsive Spectrum Disorders","score":0.05380000174045563,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11132","display_name":"Psychoanalysis and Psychopathology Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/obsessive-compulsive-symptoms","display_name":"obsessive-compulsive symptoms","score":0.9829999804496765},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.996999979019165},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":1.0},{"id":"https://openalex.org/keywords/antipsychotic-side-effects","display_name":"antipsychotic adverse effects","score":0.8360000252723694},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.8899999856948853},{"id":"https://openalex.org/keywords/young-adults","display_name":"young adults","score":0.5809999704360962},{"id":"https://openalex.org/keywords/y-bocs","display_name":"Yale-Brown Obsessive Compulsive Scale","score":0.9089999794960022},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.7670000195503235}],"concepts":[{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.964695930480957},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.9590767621994019},{"id":"https://openalex.org/C2781353949","wikidata":"https://www.wikidata.org/wiki/Q3271533","display_name":"Dopamine antagonist","level":4,"score":0.5633770227432251},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.519443690776825},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.49031975865364075},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.4751553237438202},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.46163344383239746},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.45563191175460815},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4537137746810913},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4383653402328491},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.4235111176967621},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.09053933620452881},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000208","descriptor_name":"Acute Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008137","descriptor_name":"Longitudinal Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009426","descriptor_name":"Netherlands","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D009771","descriptor_name":"Obsessive-Compulsive Disorder","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D009771","descriptor_name":"Obsessive-Compulsive Disorder","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010890","descriptor_name":"Pirenzepine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D011618","descriptor_name":"Psychotic Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011618","descriptor_name":"Psychotic Disorders","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.4088/jcp.v63n0203","doi":"https://doi.org/10.4088/jcp.v63n0203","is_oa":false,"landing_page_url":"https://doi.org/10.4088/jcp.v63n0203","pdf_url":null,"source":{"id":"https://openalex.org/S17992710","display_name":"The Journal of Clinical Psychiatry","issn_l":"0160-6689","issn":["0160-6689","1534-8628","1555-2101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4322614534","host_organization_name":"Physicians Postgraduate Press, Inc.","host_organization_lineage":["https://openalex.org/P4322614534"],"host_organization_lineage_names":["Physicians Postgraduate Press, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Clinical Psychiatry","raw_type":"journal-article"},{"id":"pmid:11874209","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11874209","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Clinical Trial"},{"id":"pmh:oai:pure.amsterdamumc.nl:openaire_cris_publications/a19b51d4-c5ba-4ab4-8c2b-e78bd67f28f7","doi":null,"is_oa":false,"landing_page_url":"https://pure.amsterdamumc.nl/en/publications/a19b51d4-c5ba-4ab4-8c2b-e78bd67f28f7","pdf_url":null,"source":{"id":"https://openalex.org/S7407055222","display_name":"Pure Amsterdam UMC","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"de Haan, L, Beuk, N, Hoogenboom, B, Dingemans, P & Linszen, D 2002, 'Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: A prospective study of 113 patients with recent-onset schizophrenia or related disorders', Journal of clinical psychiatry, vol. 63, no. 2, pp. 104-107.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:amcpub:oai:pure.amc.nl:publications/2ab5842f-191d-4b72-9a7c-78df3cde67b2","doi":null,"is_oa":false,"landing_page_url":"https://pure.amc.nl/en/publications/obsessivecompulsive-symptoms-during-treatment-with-olanzapine-and-risperidone-a-prospective-study-of-113-patients-with-recentonset-schizophrenia-or-related-disorders(2ab5842f-191d-4b72-9a7c-78df3cde67b2).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401843","display_name":"Data Archiving and Networked Services (DANS)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1322597698","host_organization_name":"Royal Netherlands Academy of Arts and Sciences","host_organization_lineage":["https://openalex.org/I1322597698"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of clinical psychiatry, 63(2), 104 - 107. Physicians Postgraduate Press Inc.","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1986864326","https://openalex.org/W3206643666","https://openalex.org/W26647938","https://openalex.org/W1981752732","https://openalex.org/W2049969525","https://openalex.org/W4387574032","https://openalex.org/W2038202398","https://openalex.org/W1995629821","https://openalex.org/W1964538442","https://openalex.org/W2920894843"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"determine":[2],"whether":[3,19],"severity":[4,27,258,280],"of":[5,21,28,36,152,189,247,259,270,281,287],"obsessive-compulsive":[6,199],"symptoms":[7],"(OCS)":[8],"differs":[9],"during":[10],"treatment":[11,23,94,153,248,288],"with":[12,46,58,76,102,156,220,241,249,285,289],"olanzapine":[13,59,88,117,157,213,221,250,271],"or":[14,49,60,63,73,92,121,130,140,158,214,272,276],"risperidone":[15,64,93,122,139,159,242,273],"and":[16,146,154,173,180,193],"to":[17,26,99,114,138,161,212,257,274],"establish":[18],"duration":[20,151,286],"antipsychotic":[22],"is":[24],"related":[25,50,256],"OCS.":[29,260,278],"METHOD:":[30],"We":[31],"conducted":[32],"a":[33],"prospective":[34],"study":[35],"consecutively":[37],"hospitalized":[38],"young":[39],"patients":[40,69,147,209],"(mean":[41],"age":[42],"=":[43,53,82,90,96,119,124,228],"22.4":[44],"years)":[45],"DSM-IV":[47,196],"schizophrenia":[48],"disorders":[51],"(N":[52,81,89,95,118,123],"113)":[54],"who":[55,70,85,112],"were":[56,71,74,184,205],"treated":[57,75,219,240],"risperidone.":[61,215],"Olanzapine":[62],"was":[65,169,251,283],"randomly":[66,210],"prescribed":[67],"for":[68,198],"drug-naive":[72],"typical":[77],"antipsychotics":[78],"before":[79],"admission":[80,100,115,137,172],"36).":[83],"Patients":[84,111],"had":[86,225],"started":[87,116],"39)":[91],"23)":[97],"prior":[98,113,160],"continued":[101],"that":[103],"medication":[104],"if":[105],"they":[106],"showed":[107,127],"initial":[108],"clinical":[109],"response.":[110],"6)":[120],"9)":[125],"but":[126],"no":[128,264],"response":[129],"suffered":[131],"from":[132],"adverse":[133],"effects":[134],"switched":[135],"at":[136,171,222,233,243],"olanzapine,":[141],"respectively.":[142],"Medical":[143],"records,":[144],"parents,":[145],"revealed":[148],"information":[149],"on":[150],"compliance":[155],"admission.":[162],"The":[163,216],"Yale-Brown":[164],"Obsessive":[165],"Compulsive":[166],"Scale":[167],"(YBOCS)":[168],"administered":[170],"6":[174,235],"weeks":[175],"thereafter.":[176],"RESULTS:":[177],"At":[178],"baseline":[179],"6-week":[181],"assessments,":[182],"OCS":[183,204,232,282],"found":[185,206],"in":[186,203,207,266],"about":[187],"30%":[188],"106":[190],"evaluable":[191],"cases":[192],"15%":[194],"met":[195],"criteria":[197],"disorder.":[200],"No":[201],"differences":[202,265],"the":[208,237,267],"assigned":[211],"35":[217],"subjects":[218,239],"both":[223,244],"assessments":[224],"significantly":[226,252],"(p":[227,253],".01)":[229,255],"more":[230],"severe":[231],"week":[234],"than":[236],"20":[238],"assessments.":[245],"Duration":[246],"<":[254],"CONCLUSION:":[261],"There":[262],"are":[263],"short-term":[268],"propensity":[269],"induce":[275],"exacerbate":[277],"However,":[279],"associated":[284],"olanzapine.":[290]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2007416161","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
